Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PHIBRO ANIMAL HEALTH CORPPAHC · Entity 4671 | Chief Operating Officer | August 06, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PHIBRO ANIMAL HEALTH CORP
Report date August 06, 2026 · Filed September 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 38,275 |
Reported balance
After 2026-08-06 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-06 · Grant · Acquired 3,726 · Balance 38,275 F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date. F3: This amendment to the Form 4 filed on August 10, 2026 (the "Original Form 4") corrects the number of RSUs granted on August 6, 2026, which was inadvertently understated in the Original Form 4 due to a calculation error. The reported amount in this amendment correctly reflects the number of RSUs granted on August 6, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.
F2: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date.
F3: This amendment to the Form 4 filed on August 10, 2026 (the "Original Form 4") corrects the number of RSUs granted on August 6, 2026, which was inadvertently understated in the Original Form 4 due to a calculation error. The reported amount in this amendment correctly reflects the number of RSUs granted on August 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2016 Filed Dec 22, 2016 02:03 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 252 | $11.83 | $2,981.16 |
DisclosureSEC source: 0001571049-16-020777 · t1603145_x2.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 02:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionOption to purchase Class A Common Stock · Derivative | 5,646 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001571049-16-019886 · t1602771_miller-f4.xml · derivative · entry 3 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,854 Underlying: Class A Common Stock · 5,646 shares Expires 2019-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2015. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 02:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | SaleClass A Common Stock | 5,646 | $30.35 | $171,356.10 |
DisclosureSEC source: 0001571049-16-019886 · t1602771_miller-f4.xml · nonDerivative · entry 2 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.65, inclusive. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 02:01 UTC | PHIBRO ANIMAL HEALTH CORP PAHC · Entity 4671 | Exercise / conversionClass A Common Stock | 5,646 | $11.83 | $66,792.18 |
DisclosureSEC source: 0001571049-16-019886 · t1602771_miller-f4.xml · nonDerivative · entry 1 Miller Larry Lee · CIK 0001603584 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.